TITLE

PBC, Ursodeoxycholic Acid and Bilirubin Watch!

AUTHOR(S)
McCashland, T. M.; Thompson, Jon S.
PUB. DATE
June 1999
SOURCE
American Journal of Gastroenterology;Jun1999, Vol. 94 Issue 6, p1444
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses research being done on the clinical significance of serum bilirubin levels under ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cirrhosis. Reference to a study A-M Bonnand, E.J. Heathcote, K.D. Lindor et al published in the 1999 issue of "Hepatology"; Comparison between the length of survival in patients whose serum bilirubin level (SBL) had normalized than in patients with elevated SBL; Significance of UCDA treatment in masking the severity of disease.
ACCESSION #
16444689

 

Related Articles

  • Relationship Between Biliary and Serum Bile Acids and Response to Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis. Lindor, K. D.; Lacerda, M. A.; Jorgensen, R. A.; DeSotel, C. K.; Batta, A. K.; Salen, G.; Dickson, E. R.; Rossi, S. S.; Hofmann, A. F. // American Journal of Gastroenterology;Sep1998, Vol. 93 Issue 9, p1498 

    Objective: Ursodeoxycholic acid (UDCA) improves liver biochemistries and enriches the bile with UDCA in patients with primary biliary cirrhosis. The aim of this study was to determine whether the degree of enrichment of bile correlated with that of serum and whether either of these measures...

  • Prolonged Follow-Up of Patients in the U.S. Multicenter Trial of Ursodeoxycholic Acid for Primary Biliary Cirrhosis. Combes, Burton; Luketic, Velimir A.; Peters, Marion G.; Zetterman, Rowen K.; Garcia-Tsao, Guadalupe; Munoz, Santiago J.; Lin, Danyu; Flye, Nancy; Carithers, Robert L. // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p264 

    OBJECTIVE: Randomized, double-blind, placebo-controlled trials of ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) have not demonstrated improvement in survival during the placebo-controlled phases of these trials. Analyses purporting to demonstrate a survival...

  • NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. Berzigotti, Annalisa; Bellot, Pau; De Gottardi, Andrea; Garcia-Pagan, Juan Carlos; Gagnon, Caroline; Spénard, Jean; Bosch, Jaime // American Journal of Gastroenterology;May2010, Vol. 105 Issue 5, p1094 

    OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), which showed selective vasodilatory effect on intrahepatic circulation in animal models of cirrhosis. This study was aimed at testing the...

  • Management Challenges of Liver Cirrhosis. Sadovsky, Richard // American Family Physician;2/15/2000, Vol. 61 Issue 4, p1127 

    Provides information on the study `Cirrhosis of Liver,' by B.S. Anand published in the August 1999 issue of the `Western Journal of Medicine.'

  • Mercaptopurine.  // Reactions Weekly;Aug2014, Vol. 1512 Issue 1, p27 

    The article presents a case study of a 12-year-old boy who was admitted to hospital for non-cirrhotic portal hypertension after being treated for Cohn's disease (CD).

  • DECOMPENSATED CIRRHOSIS; PREVALENCE OF GASTRIC VARICES. Iqbal, Sarwat; Yousaf, Muhammad Haroon; Yousuf, Muhammad Ifitikhar; Wasim-Uddin // Professional Medical Journal;2015, Vol. 22 Issue 11, p1397 

    Cirrhosis with subsequent portal hypertension is a major health problem worldwide. Among various etiologies, HCV is the leading cause of chronic hepatocellular injury. Cirrhosis being the commonest cause of portal hypertension results in a spectrum of complications. Approximately 5-15% of...

  • Idiopathic Presinusoidal Portal Hypertension (Banti's Syndrome). Polish, Edwin; Christie, John; Cohen, Arthur; Sullivan Jr., Benjamin // Annals of Internal Medicine;Apr62, Vol. 56 Issue 4, p624 

    Presents the case of a 23-year-old Caucasian male that bears resemblance to the early stages of Banti's syndrome, characterized by splenomegaly and cirrhosis of the liver. Stages of the disease; Indications that the portal hypertension was presinusoidal in origin; Absence of neurological...

  • New weapon for primary biliary cirrhosis from Japan. Zeniya, Mikio // Journal of Gastroenterology;2003, Vol. 38 Issue 6, p619 

    Editorial. Studies the use of ursodeoxycholic acid (UDCA) for treating patients with primary biliary cirrhosis in Japan. Symptoms of the disease; Immunological properties of UDCA.

  • Incomplete Response to Ursodeoxycholic Acid in Primary Biliary Cirrhosis: Is a Double Dosage Worthwhile? Angulo, Paul; Jorgensen, Roberta A.; Lindor, Keith D. // American Journal of Gastroenterology;Nov2001, Vol. 96 Issue 11, p3152 

    OBJECTIVE: The aim of this study was to assess the safety and efficacy of high-dose ursodeoxycholic acid (UDCA, 28-32 mg/kg/day) in patients with primary biliary cirrhosis (PBC) who had shown an incomplete response to the standard dose (13-15 mg/kg/day). METHODS: A total of 25 patients with PBC...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics